Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Fair Value

Margin Of Safety %

Put/Call OI Ratio

0.31

Float Short​ %​

21.62

EPS 1 Diff

-1.21

EPS Year Diff

1.31

Ticker: FULC




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-09-06FULC8.540.500.08117607
2024-09-09FULC8.630.5015.13118068
2024-09-10FULC8.410.550.63122293
2024-09-11FULC8.870.552.41123893
2024-09-12FULC3.430.571.91126095
2024-09-13FULC3.180.472.01118601
2024-09-16FULC3.180.451.29117263
2024-09-17FULC3.490.452.17117203
2024-09-18FULC3.440.464.36117387
2024-09-19FULC3.450.460.13117429
2024-09-20FULC3.340.460.24117382
2024-09-23FULC3.20.420.48111110
2024-09-24FULC3.20.420.62111087
2024-09-25FULC3.460.4271.88111089
2024-09-26FULC4.010.355.50105395
2024-09-27FULC3.780.300.60102484
2024-09-30FULC3.580.310.19103192
2024-10-01FULC3.610.310.53103197
2024-10-02FULC3.880.310.00103214
2024-10-03FULC3.660.310.00103234
2024-10-04FULC3.810.311.05103304
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-09-06FULC8.55-5.1- -0.38
2024-09-09FULC8.64-5.1- -0.38
2024-09-10FULC8.43-5.1- -0.38
2024-09-11FULC8.87-5.1- -0.38
2024-09-12FULC3.45-5.1- -0.38
2024-09-13FULC3.18-5.1- -0.38
2024-09-16FULC3.18-5.1- -0.31
2024-09-17FULC3.49-5.1- -0.29
2024-09-18FULC3.44-5.1- -0.29
2024-09-19FULC3.46-5.1- -0.28
2024-09-20FULC3.34-5.1- -0.28
2024-09-23FULC3.20-5.1- -0.28
2024-09-24FULC3.20-5.1- -0.28
2024-09-25FULC3.47-5.1- -0.28
2024-09-26FULC4.00-5.1- -0.28
2024-09-27FULC3.77-5.1- -0.28
2024-09-30FULC3.58-5.1- -0.28
2024-10-01FULC3.61-5.1- -0.28
2024-10-02FULC3.87-5.1- -0.28
2024-10-03FULC3.67-5.1- -0.28
2024-10-04FULC3.81-5.1- -0.28
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-09-06FULC-0.1126.1214.13
2024-09-09FULC-0.0126.1214.13
2024-09-10FULC-0.0126.1214.13
2024-09-11FULC-0.0126.1214.13
2024-09-12FULC-0.0126.1213.96
2024-09-13FULC-0.0126.1213.96
2024-09-16FULC-0.0126.1213.96
2024-09-17FULC-0.0126.1213.96
2024-09-18FULC-0.0126.1213.96
2024-09-19FULC-0.0126.1213.96
2024-09-20FULC-0.0126.1213.96
2024-09-23FULC-0.0126.1213.96
2024-09-24FULC-0.0126.1213.96
2024-09-25FULC-0.0126.1219.74
2024-09-26FULC-0.0026.1221.62
2024-09-27FULC-0.0026.1221.62
2024-09-30FULC-0.0023.5321.62
2024-10-01FULC-0.0023.5321.62
2024-10-02FULC-0.0023.5321.62
2024-10-03FULC-0.0023.5321.62
2024-10-04FULC-0.0023.5321.62
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.87

Avg. EPS Est. Current Quarter

-0.41

Avg. EPS Est. Next Quarter

-0.34

Insider Transactions

Institutional Transactions

23.53

Beta

2.21

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value (Academic)

Quality Score

29

Growth Score

39

Sentiment Score

85

Actual DrawDown %

88.5

Max Drawdown 5-Year %

-92.7

Target Price

5.5

P/E

Forward P/E

PEG

P/S

2.92

P/B

0.87

P/Free Cash Flow

EPS

-0.35

Average EPS Est. Cur. Y​

-0.28

EPS Next Y. (Est.)

-1.23

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-24.79

Relative Volume

0.41

Return on Equity vs Sector %

-29

Return on Equity vs Industry %

-50.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.1

EBIT Estimation

Fulcrum Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 76
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
stock quote shares FULC – Fulcrum Therapeutics Inc Stock Price stock today
news today FULC – Fulcrum Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FULC – Fulcrum Therapeutics Inc yahoo finance google finance
stock history FULC – Fulcrum Therapeutics Inc invest stock market
stock prices FULC premarket after hours
ticker FULC fair value insiders trading